Pub Date : 2022-09-30DOI: 10.4274/turkderm.galenos.2022.99835
Anandika Pawitri, S. Menaldi, M. Marissa
Background and Design: To investigate the association between sociodemographic variables, illness duration, leprosy types, comorbidities, and World Health Organization disability grading system for leprosy with daily activity limitations in people with leprosy who had completed multidrug therapy. Materials and Methods: A cross-sectional study was conducted in Sitanala Leprosy Village, Tangerang, Indonesia, in April 2018. Sociodemographic data and leprosy baseline characteristics were obtained from patients with leprosy who had completed multidrug therapy. The Screening of Activity Limitation and Safety Awareness scale was used to measure limitations in performing daily functional activities. Results: A total of 205 people were included in the study, of which 39 (19%) had eye disabilities, 178 (86.8%) had hand disabilities, and 187 (91.2%) had foot disabilities. A total of 135 (65.8%) people had mild-to-moderate functional limitation, and 33 (16%) had severe-to-very severe functional limitation. The proportion of unemployed individuals was higher among those with severe-extreme limitation compared to those without significant limitation (p=0.01). Individuals with eye disability had a higher risk of having severe-extreme activity limitation compared to those without eye disability (p=0.008). A dose-response association of hands and foot disabilities with activity limitation was found; the adjusted odds ratio (OR) of the association of hands and foot disabilities with mild-moderate activity limitation was 3.03 (p=0.012), and the association was greater with severe-extreme activity limitation (adjusted OR; 20.38, p=0.006). Conclusion: Severe disability is associated with functional activity limitations. The findings of the present study can guide healthcare providers in designing appropriate prevention and intervention services for patients with leprosy-related disabilities.
背景与设计:研究完成多药治疗的麻风病患者每日活动受限麻风病的社会人口学变量、病程、麻风病类型、合并症和世界卫生组织残疾分级系统之间的关系。材料与方法:于2018年4月在印度尼西亚Tangerang的Sitanala麻风病村进行了一项横断面研究。从完成多药治疗的麻风病患者中获得社会人口学数据和麻风病基线特征。活动限制筛选和安全意识量表用于测量日常功能活动的限制。结果:共纳入205人，其中眼残39人(19%)，手残178人(86.8%)，足残187人(91.2%)。共有135人(65.8%)有轻度至中度功能限制，33人(16%)有严重至非常严重的功能限制。严重-极端限制组的失业人口比例高于无显著限制组(p=0.01)。与没有眼残疾的人相比，有眼残疾的人发生严重极端活动限制的风险更高(p=0.008)。发现手脚残疾与活动受限存在剂量-反应关联;手足残疾与轻中度活动受限相关的校正比值比(OR)为3.03 (p=0.012)，与重度-极端活动受限相关的校正比值比(OR;20.38, p = 0.006)。结论:重度残疾与功能活动受限有关。本研究结果可指导卫生保健提供者为麻风相关残疾患者设计适当的预防和干预服务。
{"title":"Factors contributing to activity limitations in Leprosy patients in Sitanala Leprosy Village, Indonesia","authors":"Anandika Pawitri, S. Menaldi, M. Marissa","doi":"10.4274/turkderm.galenos.2022.99835","DOIUrl":"https://doi.org/10.4274/turkderm.galenos.2022.99835","url":null,"abstract":"Background and Design: To investigate the association between sociodemographic variables, illness duration, leprosy types, comorbidities, and World Health Organization disability grading system for leprosy with daily activity limitations in people with leprosy who had completed multidrug therapy. Materials and Methods: A cross-sectional study was conducted in Sitanala Leprosy Village, Tangerang, Indonesia, in April 2018. Sociodemographic data and leprosy baseline characteristics were obtained from patients with leprosy who had completed multidrug therapy. The Screening of Activity Limitation and Safety Awareness scale was used to measure limitations in performing daily functional activities. Results: A total of 205 people were included in the study, of which 39 (19%) had eye disabilities, 178 (86.8%) had hand disabilities, and 187 (91.2%) had foot disabilities. A total of 135 (65.8%) people had mild-to-moderate functional limitation, and 33 (16%) had severe-to-very severe functional limitation. The proportion of unemployed individuals was higher among those with severe-extreme limitation compared to those without significant limitation (p=0.01). Individuals with eye disability had a higher risk of having severe-extreme activity limitation compared to those without eye disability (p=0.008). A dose-response association of hands and foot disabilities with activity limitation was found; the adjusted odds ratio (OR) of the association of hands and foot disabilities with mild-moderate activity limitation was 3.03 (p=0.012), and the association was greater with severe-extreme activity limitation (adjusted OR; 20.38, p=0.006). Conclusion: Severe disability is associated with functional activity limitations. The findings of the present study can guide healthcare providers in designing appropriate prevention and intervention services for patients with leprosy-related disabilities.","PeriodicalId":49412,"journal":{"name":"Turkderm-Archives of the Turkish Dermatology and Venerology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44713042","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-09-30DOI: 10.4274/turkderm.galenos.2022.98957
C. B. Türk, Dilara Ilhan, Ozan Erdem, M. Gürel, A. E. Koku Aksu
{"title":"Cutis marmorata telangiectatica congenita on hand and forearm: Initial and follow-up observations of a rare case","authors":"C. B. Türk, Dilara Ilhan, Ozan Erdem, M. Gürel, A. E. Koku Aksu","doi":"10.4274/turkderm.galenos.2022.98957","DOIUrl":"https://doi.org/10.4274/turkderm.galenos.2022.98957","url":null,"abstract":"","PeriodicalId":49412,"journal":{"name":"Turkderm-Archives of the Turkish Dermatology and Venerology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45410214","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-09-30DOI: 10.4274/turkderm.galenos.2022.01460
Gülistan Maçin
{"title":"What is your diagnosis?","authors":"Gülistan Maçin","doi":"10.4274/turkderm.galenos.2022.01460","DOIUrl":"https://doi.org/10.4274/turkderm.galenos.2022.01460","url":null,"abstract":"","PeriodicalId":49412,"journal":{"name":"Turkderm-Archives of the Turkish Dermatology and Venerology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47737670","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-09-30DOI: 10.4274/turkderm.galenos.2022.30776
Semih Güder, Hüsna Güder
{"title":"Serum vitamin B12, ferritin, and vitamin D levels in patients with seborrheic dermatitis: A case-control study","authors":"Semih Güder, Hüsna Güder","doi":"10.4274/turkderm.galenos.2022.30776","DOIUrl":"https://doi.org/10.4274/turkderm.galenos.2022.30776","url":null,"abstract":"","PeriodicalId":49412,"journal":{"name":"Turkderm-Archives of the Turkish Dermatology and Venerology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46196164","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-09-30DOI: 10.4274/turkderm.galenos.2022.07347
Y. Gürsel Ürün, E. Usturalı Keskin
Background and Design: Morphea is also known as localized scleroderma. It is a rare autoimmune skin disease characterized by inflammation and sclerosis in the dermis and sometimes in the subcutaneous tissue. Laboratory findings, imaging, and histopathological features facilitate diagnosis and provide sufficient information about disease severity. Clinicopathologic correlations and severity factors in morphea are poorly described. Thus, this study aimed to review the clinical and histopathological features and treatment responses of patients with morphea and compare these features with disease activity and damage scores to identify new tools for assessing disease severity other than clinical findings. The applicability of the Localized Scleroderma Cutaneous Assessment Tool in clinical practice was also evaluated. Materials and Methods: This study reviewed data of 41 patients who had a histopathologically confirmed diagnosis of morphea and had been followed up regularly for at least 6 months. The modified Localized Scleroderma Skin Severity Index (mLoSSI), Localized Scleroderma Skin Damage Index (LoSDI), Physician Global Assessment-Activity (PGA-A), and Physician Global Assessment-Damage (PGA-D) were calculated at baseline and final treatment. Results: Among morphea subtypes, superficial morphea had significantly more sclerosis in the papillary dermis and plaque-type morphea had significantly more sclerosis in the reticular dermis (p<0.05). When positive antinuclear antibody (ANA) and high levels of thyroid autoantibodies were compared with mLoSSI, LoSDI, PGA-A, and PGA-D scores at baseline, no significant correlation was found. Comparison of the subgroups according to the initial mLoSSI and LoSDI scores revealed no significant histopathological differences between the groups. Conclusion: Although the mLoSSI, LoSDI, PGA-A, and PGA-D scores can be successfully used for the follow-up and treatment of patients with morphea, no correlation was found between positive ANA, high levels of thyroid autoantibodies, and histopathological features. autoimmune diseases, clinical symptoms, and concomitant lichen sclerosus et atrophicus (LSA) were recorded. Laboratory results, detailed treatment modalities, treatment duration, and treatment responses were assessed. The same dermatologist performed a biopsy of the erythematous rim of the inflammatory lesions or central sclerosis of the lesions that did not clinically show inflammation using a 4 mm punch biopsy instrument. Incisional biopsy was performed in patients with a provisional diagnosis of linear morphea, deep type morphea, or eosinophilic fasciitis.
{"title":"Association between Localized Scleroderma Cutaneous Assessment Tool and clinicopathologic characteristics in patients with morphea","authors":"Y. Gürsel Ürün, E. Usturalı Keskin","doi":"10.4274/turkderm.galenos.2022.07347","DOIUrl":"https://doi.org/10.4274/turkderm.galenos.2022.07347","url":null,"abstract":"Background and Design: Morphea is also known as localized scleroderma. It is a rare autoimmune skin disease characterized by inflammation and sclerosis in the dermis and sometimes in the subcutaneous tissue. Laboratory findings, imaging, and histopathological features facilitate diagnosis and provide sufficient information about disease severity. Clinicopathologic correlations and severity factors in morphea are poorly described. Thus, this study aimed to review the clinical and histopathological features and treatment responses of patients with morphea and compare these features with disease activity and damage scores to identify new tools for assessing disease severity other than clinical findings. The applicability of the Localized Scleroderma Cutaneous Assessment Tool in clinical practice was also evaluated. Materials and Methods: This study reviewed data of 41 patients who had a histopathologically confirmed diagnosis of morphea and had been followed up regularly for at least 6 months. The modified Localized Scleroderma Skin Severity Index (mLoSSI), Localized Scleroderma Skin Damage Index (LoSDI), Physician Global Assessment-Activity (PGA-A), and Physician Global Assessment-Damage (PGA-D) were calculated at baseline and final treatment. Results: Among morphea subtypes, superficial morphea had significantly more sclerosis in the papillary dermis and plaque-type morphea had significantly more sclerosis in the reticular dermis (p<0.05). When positive antinuclear antibody (ANA) and high levels of thyroid autoantibodies were compared with mLoSSI, LoSDI, PGA-A, and PGA-D scores at baseline, no significant correlation was found. Comparison of the subgroups according to the initial mLoSSI and LoSDI scores revealed no significant histopathological differences between the groups. Conclusion: Although the mLoSSI, LoSDI, PGA-A, and PGA-D scores can be successfully used for the follow-up and treatment of patients with morphea, no correlation was found between positive ANA, high levels of thyroid autoantibodies, and histopathological features. autoimmune diseases, clinical symptoms, and concomitant lichen sclerosus et atrophicus (LSA) were recorded. Laboratory results, detailed treatment modalities, treatment duration, and treatment responses were assessed. The same dermatologist performed a biopsy of the erythematous rim of the inflammatory lesions or central sclerosis of the lesions that did not clinically show inflammation using a 4 mm punch biopsy instrument. Incisional biopsy was performed in patients with a provisional diagnosis of linear morphea, deep type morphea, or eosinophilic fasciitis.","PeriodicalId":49412,"journal":{"name":"Turkderm-Archives of the Turkish Dermatology and Venerology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43467637","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-09-30DOI: 10.4274/turkderm.galenos.2022.90132
E. Acar, Kemal Özyurt, R. Akyol
Background and Design: Systemic retinoids are commonly used medications in dermatology and indicated in various skin disorders such as acne vulgaris and psoriasis. Data about the risk of Coronavirus disease-2019 (COVID-19) in patients using systemic retinoids are limited. Thus, this study aimed to investigate the risk of COVID-19 in patients undergoing systemic retinoid therapy. Materials and Methods: A total of 186 patients who have undergone systemic isotretinoin and acitretin therapy were recruited. Patients who presented to the dermatology clinic for various skin diseases, such as eczema, vitiligo, tinea, etc., who were not on systemic retinoid therapy, and who received topical medications comprised the control group. The development of COVID-19 in the retinoid therapy group and the control group was retrospectively reviewed using hospital database. Results: The mean age of the patients in the retinoid therapy group was 25.72 +/- 0.67 and that in the control group was 25.4 +/- 0.62. Moreover,165 patients received isotretinoin, and 21 patients received acitretin treatment. The isotretinoin dosage ranged from 0.5 to 0.8 mg/kg wheras the acitretin dosage ranged between 10 and 25 mg/day. Two patients (1.07%) in the retinoid therapy group and 8 (4.3%) patients in the control group were diagnosed with COVID-19. None of the patients receiving acitretin was diagnosed with COVID-19. COVID-19 diagnosis was established in the 2nd and 3rd months of isotretinoin treatment, and lung involvement was not observed. No significant difference regarding the number of COVID-19 cases and disease severity was found between the two groups (p=0.105;p=0.258, respectively). Conclusion: Isotretinoin and acitretin use was not associated with increased COVID-19 risk or disease severity. Systemic retinoids appear to be a safe treatment modality in the COVID-19 era.
{"title":"Evaluation of COVID-19 risk in patients on systemic retinoid therapy","authors":"E. Acar, Kemal Özyurt, R. Akyol","doi":"10.4274/turkderm.galenos.2022.90132","DOIUrl":"https://doi.org/10.4274/turkderm.galenos.2022.90132","url":null,"abstract":"Background and Design: Systemic retinoids are commonly used medications in dermatology and indicated in various skin disorders such as acne vulgaris and psoriasis. Data about the risk of Coronavirus disease-2019 (COVID-19) in patients using systemic retinoids are limited. Thus, this study aimed to investigate the risk of COVID-19 in patients undergoing systemic retinoid therapy. Materials and Methods: A total of 186 patients who have undergone systemic isotretinoin and acitretin therapy were recruited. Patients who presented to the dermatology clinic for various skin diseases, such as eczema, vitiligo, tinea, etc., who were not on systemic retinoid therapy, and who received topical medications comprised the control group. The development of COVID-19 in the retinoid therapy group and the control group was retrospectively reviewed using hospital database. Results: The mean age of the patients in the retinoid therapy group was 25.72 +/- 0.67 and that in the control group was 25.4 +/- 0.62. Moreover,165 patients received isotretinoin, and 21 patients received acitretin treatment. The isotretinoin dosage ranged from 0.5 to 0.8 mg/kg wheras the acitretin dosage ranged between 10 and 25 mg/day. Two patients (1.07%) in the retinoid therapy group and 8 (4.3%) patients in the control group were diagnosed with COVID-19. None of the patients receiving acitretin was diagnosed with COVID-19. COVID-19 diagnosis was established in the 2nd and 3rd months of isotretinoin treatment, and lung involvement was not observed. No significant difference regarding the number of COVID-19 cases and disease severity was found between the two groups (p=0.105;p=0.258, respectively). Conclusion: Isotretinoin and acitretin use was not associated with increased COVID-19 risk or disease severity. Systemic retinoids appear to be a safe treatment modality in the COVID-19 era.","PeriodicalId":49412,"journal":{"name":"Turkderm-Archives of the Turkish Dermatology and Venerology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47728377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-09-30DOI: 10.4274/turkderm.galenos.2022.12499
S. Taşan, C. Tataroğlu, E. Savk, Fatma Nalbant
A unique Abstract Trichofolliculoma is a rare benign cystic nodule, consisting of a central dilated hair follicle that radiates into the surrounding dermis. Trichofolliculoma presents as a dome-shaped, solitary, 0.5-1.0 cm diameter of papule or nodule with a central pore. The clinical differential diagnosis of trichofolliculoma includes basal cell carcinoma, milia, keratoacanthoma, trichoepithelioma, and syringoma. Histopathological differential diagnosis includes trichoepithelioma, dilated pore of Winer, pilar sheath acanthoma, and basal cell carcinoma. Trichofollicumas usually occur on the face and less frequently on the neck and scalp. The gluteal area is an unprecedented site for trichofolliculoma although some unusual locations were observed. Herein, we report a very rare trichofolliculoma of the gluteal area which was not reported in English literature. gluteal
{"title":"Trichofolliculoma on gluteal area: A unique case report","authors":"S. Taşan, C. Tataroğlu, E. Savk, Fatma Nalbant","doi":"10.4274/turkderm.galenos.2022.12499","DOIUrl":"https://doi.org/10.4274/turkderm.galenos.2022.12499","url":null,"abstract":"A unique Abstract Trichofolliculoma is a rare benign cystic nodule, consisting of a central dilated hair follicle that radiates into the surrounding dermis. Trichofolliculoma presents as a dome-shaped, solitary, 0.5-1.0 cm diameter of papule or nodule with a central pore. The clinical differential diagnosis of trichofolliculoma includes basal cell carcinoma, milia, keratoacanthoma, trichoepithelioma, and syringoma. Histopathological differential diagnosis includes trichoepithelioma, dilated pore of Winer, pilar sheath acanthoma, and basal cell carcinoma. Trichofollicumas usually occur on the face and less frequently on the neck and scalp. The gluteal area is an unprecedented site for trichofolliculoma although some unusual locations were observed. Herein, we report a very rare trichofolliculoma of the gluteal area which was not reported in English literature. gluteal","PeriodicalId":49412,"journal":{"name":"Turkderm-Archives of the Turkish Dermatology and Venerology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45873217","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-09-30DOI: 10.4274/turkderm.galenos.2022.11455
Müge Göre Karaali, G. Issın, Soner Karaali, Şevki Özdemir
Coronavirus disease-2019 (COVID-19) caused by the severe acute respiratory syndrome-coronavirus-2, which became a pandemic, may have cutaneous findings. Eccrine chromhidrosis is a rare disorder characterized by the excretion of colored sweat via the eccrine sweat glands. We present eccrine chromhidrosis in two COVID-19 cases treated with favipiravir.
{"title":"Eccrine chromhidrosis in severe acute respiratory syndromecoronavirus- 2 virus infection treated with favipiravir","authors":"Müge Göre Karaali, G. Issın, Soner Karaali, Şevki Özdemir","doi":"10.4274/turkderm.galenos.2022.11455","DOIUrl":"https://doi.org/10.4274/turkderm.galenos.2022.11455","url":null,"abstract":"Coronavirus disease-2019 (COVID-19) caused by the severe acute respiratory syndrome-coronavirus-2, which became a pandemic, may have cutaneous findings. Eccrine chromhidrosis is a rare disorder characterized by the excretion of colored sweat via the eccrine sweat glands. We present eccrine chromhidrosis in two COVID-19 cases treated with favipiravir.","PeriodicalId":49412,"journal":{"name":"Turkderm-Archives of the Turkish Dermatology and Venerology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46532938","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-06-30DOI: 10.4274/turkderm.galenos.2022.57804
Parwaaz Matharoo, Saurabh Sharma, Jasleen Kaur, R. Bassi
{"title":"Comparison of the efficacy of microneedling combined with 5-fluorouracil 5% cream versus microneedling combined with tacrolimus 0.1% ointment in the treatment of vitiligo","authors":"Parwaaz Matharoo, Saurabh Sharma, Jasleen Kaur, R. Bassi","doi":"10.4274/turkderm.galenos.2022.57804","DOIUrl":"https://doi.org/10.4274/turkderm.galenos.2022.57804","url":null,"abstract":"","PeriodicalId":49412,"journal":{"name":"Turkderm-Archives of the Turkish Dermatology and Venerology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48665904","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-06-30DOI: 10.4274/turkderm.galenos.2022.14412
R. Ottevanger, R. Genders
{"title":"What is your diagnosis?","authors":"R. Ottevanger, R. Genders","doi":"10.4274/turkderm.galenos.2022.14412","DOIUrl":"https://doi.org/10.4274/turkderm.galenos.2022.14412","url":null,"abstract":"","PeriodicalId":49412,"journal":{"name":"Turkderm-Archives of the Turkish Dermatology and Venerology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41567836","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：